Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.
Original title: “Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand”
Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to break through where others have previously failed.
Original title: “5 drugmakers chasing Merck and Moderna in the cancer vaccine race”
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer,... Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. He said Medicus Pharma was therefore adequately funded, and potentially fully funded, to pick up where Pfizer left off with a Phase 1 dose-escalation study. He described the addition of the program as a “paradigm shift” in the company’s portfolio, providing an opportunity for Medicus Pharma to refine its position as a precision oncology-led biotech life sciences company. He also pointed to the potential commercial characteristics of the rare disease opportunity. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.
Original title: “Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI | NASDAQ:MDCX”
The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.
Original title: “Samsung Biologics inks $262M manufacturing deal with European pharma company”
The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the FDA’s approval last month for Mimrylo.
Original title: “Disc sets up polycythemia vera challenge but Silence maintains lead”
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
Original title: “mRNA cancer vaccines’ biggest barriers to market”
Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
Original title: “Novartis drags peers down with triple asset stumble”
Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
Original title: “Novartis drags peers down with triple asset failure”
CONNECTA Therapeutics secures €3.1M funding to advance CTH120, a TrkB modulator, into mid-stage trials for Fragile X syndrome treatment. Read more. CONNECTA TherapeuticsCTH120Fragile X syndromeTrkB modulatorclinical trial fundingrare diseaseneuroplasticityBarcelona biotechFXS treatmentneurodevelopmental disorder In parallel, CONNECTA is advancing preparations for a pediatric development programme under the FRAXCURE project, co-funded by the European Innovation Council. CEO Jordi Fàbrega said the company expects Phase IIa data in mid-2027 to represent a meaningful step in demonstrating CTH120's potential to address the underlying biology of the disease. Barcelona-based CONNECTA Therapeutics has closed a EUR 3.1 million (USD 3.4 million) financing round to support the clinical development of CTH120, its small-molecule neuroplasticity modulator in Fragile X syndrome (FXS), a rare neurodevelopmental disorder for which no approved targeted therapies currently exist. The round was led by Clave Capital, a new investor entering via its Innvierte Science Tech Clave Innohealth, F.C.R. fund, with participation from existing backers Inveready, CDTI Innvierte, and the Prous Institute for Biomedical Research. The financing follows a EUR 1.7 million seed round raised in 2020 led by Inveready and CDTI Innvierte, and complements substantial non-dilutive funding the company has secured over the same period, including a EUR 2.7 million grant from the Spanish Ministry of Science and the European Union's NextGeneration EU programme to fund the Phase IIa trial directly.
Original title: “CONNECTA raises EUR 3.1m to advance TrkB modulator into mid-stage Fragile X trial”
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
Original title: “Novartis’ board faces investor scrutiny after M&A misfires and R&D flops”
HRSA is providing additional award funds to 11 current ITCP-- State Award recipients previously funded under HRSA-22-73 to support the continuation and expansion of existing activities to build state and local capacity and implement the infant-toddler court approach in federal fiscal year (FY) 2026.
Original title: “Notice of Supplemental Funding, Infant-Toddler Court Program-State Awards”
A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit.
Original title: “Takeda’s long-term R&D head announces exit after major pipeline reorganization”
Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”
Original title: “Andy Plump, architect of Takeda’s R&D overhaul, to retire next year”
Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
Original title: “Tyra shares slip as bladder cancer responses fall short of investor expectations”
Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
Original title: “A booming business on Wall Street would love more biotechs to quietly die”